234 related articles for article (PubMed ID: 21593776)
1. Mechanisms of resistance to RAF inhibitors in melanoma.
Aplin AE; Kaplan FM; Shao Y
J Invest Dermatol; 2011 Sep; 131(9):1817-20. PubMed ID: 21593776
[TBL] [Abstract][Full Text] [Related]
2. Resistance to RAF inhibitors revisited.
Hartsough E; Shao Y; Aplin AE
J Invest Dermatol; 2014 Feb; 134(2):319-325. PubMed ID: 24108405
[TBL] [Abstract][Full Text] [Related]
3. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS
Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323
[TBL] [Abstract][Full Text] [Related]
4. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.
Wagle N; Emery C; Berger MF; Davis MJ; Sawyer A; Pochanard P; Kehoe SM; Johannessen CM; Macconaill LE; Hahn WC; Meyerson M; Garraway LA
J Clin Oncol; 2011 Aug; 29(22):3085-96. PubMed ID: 21383288
[TBL] [Abstract][Full Text] [Related]
5. Bench to bedside: mechanistic principles of targeting the RAF kinase in melanoma.
Rajakulendran T; Adam DN
Int J Dermatol; 2014 Dec; 53(12):1428-33. PubMed ID: 25311997
[TBL] [Abstract][Full Text] [Related]
6. [Advances in clinical treatment of malignant melanoma: B-RAF kinase inhibition].
Heneberg P
Klin Onkol; 2011; 24(4):256-64. PubMed ID: 21905615
[TBL] [Abstract][Full Text] [Related]
7. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.
Shi H; Kong X; Ribas A; Lo RS
Cancer Res; 2011 Aug; 71(15):5067-74. PubMed ID: 21803746
[TBL] [Abstract][Full Text] [Related]
8. Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells.
Basile KJ; Abel EV; Aplin AE
Oncogene; 2012 May; 31(19):2471-9. PubMed ID: 21996740
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
[TBL] [Abstract][Full Text] [Related]
10. A STATement on vemurafenib-resistant melanoma.
Hartsough EJ; Aplin AE
J Invest Dermatol; 2013 Aug; 133(8):1928-9. PubMed ID: 23856932
[TBL] [Abstract][Full Text] [Related]
11. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.
Rubinstein JC; Sznol M; Pavlick AC; Ariyan S; Cheng E; Bacchiocchi A; Kluger HM; Narayan D; Halaban R
J Transl Med; 2010 Jul; 8():67. PubMed ID: 20630094
[TBL] [Abstract][Full Text] [Related]
12. Community experience of vemurafenib for BRAF(V600) melanoma.
Hersey P
Lancet Oncol; 2014 Apr; 15(4):369-70. PubMed ID: 24582506
[No Abstract] [Full Text] [Related]
13. [Zelboraf. Longer term survival for advanced stage melanoma].
Sabourin G
Perspect Infirm; 2012; 9(5):64-5. PubMed ID: 22978138
[No Abstract] [Full Text] [Related]
14. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
Owen JL; Lopez IE; Desai SR
J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
[TBL] [Abstract][Full Text] [Related]
15. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.
Atefi M; von Euw E; Attar N; Ng C; Chu C; Guo D; Nazarian R; Chmielowski B; Glaspy JA; Comin-Anduix B; Mischel PS; Lo RS; Ribas A
PLoS One; 2011; 6(12):e28973. PubMed ID: 22194965
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.
Bollag G; Hirth P; Tsai J; Zhang J; Ibrahim PN; Cho H; Spevak W; Zhang C; Zhang Y; Habets G; Burton EA; Wong B; Tsang G; West BL; Powell B; Shellooe R; Marimuthu A; Nguyen H; Zhang KY; Artis DR; Schlessinger J; Su F; Higgins B; Iyer R; D'Andrea K; Koehler A; Stumm M; Lin PS; Lee RJ; Grippo J; Puzanov I; Kim KB; Ribas A; McArthur GA; Sosman JA; Chapman PB; Flaherty KT; Xu X; Nathanson KL; Nolop K
Nature; 2010 Sep; 467(7315):596-9. PubMed ID: 20823850
[TBL] [Abstract][Full Text] [Related]
17. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
Seeley AR; De Los Santos JF; Conry RM
Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037
[TBL] [Abstract][Full Text] [Related]
18. PLX4032 and melanoma: resistance, expectations and uncertainty.
Roukos DH
Expert Rev Anticancer Ther; 2011 Mar; 11(3):325-8. PubMed ID: 21417847
[No Abstract] [Full Text] [Related]
19. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
20. Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma.
Yadav V; Zhang X; Liu J; Estrem S; Li S; Gong XQ; Buchanan S; Henry JR; Starling JJ; Peng SB
J Biol Chem; 2012 Aug; 287(33):28087-98. PubMed ID: 22730329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]